ABT-199 (Venetoclax) is a promising and selective inhibitor of Bcl-2 protein, which has exhibited clinical efficacy in multiple hematological cancers [170]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.